Wells Fargo’s Pulse Biosciences PLSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $199K | Sell |
9,195
-12,954
| -58% | -$239K | ﹤0.01% | 4706 |
|
|
2025
Q4 | $304K | Buy |
22,149
+8,502
| +62% | +$132K | ﹤0.01% | 4827 |
|
|
2025
Q3 | $242K | Buy |
13,647
+926
| +7% | +$14.6K | ﹤0.01% | 4828 |
|
|
2025
Q2 | $192K | Buy |
12,721
+1,148
| +10% | +$19K | ﹤0.01% | 4798 |
|
|
2025
Q1 | $186K | Buy |
11,573
+258
| +2% | +$4.81K | ﹤0.01% | 4762 |
|
|
2024
Q4 | $197K | Buy |
11,315
+2,416
| +27% | +$42.6K | ﹤0.01% | 4813 |
|
|
2024
Q3 | $156K | Buy |
8,899
+537
| +6% | +$9.16K | ﹤0.01% | 4742 |
|
|
2024
Q2 | $93.6K | Buy |
8,362
+367
| +5% | +$3.46K | ﹤0.01% | 4977 |
|
|
2024
Q1 | $69.6K | Sell |
7,995
-5,289
| -40% | -$48.6K | ﹤0.01% | 5099 |
|
|
2023
Q4 | $163K | Sell |
13,284
-1,625
| -11% | -$11.3K | ﹤0.01% | 4601 |
|
|
2023
Q3 | $60.1K | Sell |
14,909
-2,488
| -14% | -$15.5K | ﹤0.01% | 5083 |
|
|
2023
Q2 | $125K | Buy |
17,397
+8,694
| +100% | +$55.5K | ﹤0.01% | 4896 |
|
|
2023
Q1 | $29.2K | Sell |
8,703
-1,848
| -18% | -$5.57K | ﹤0.01% | 5458 |
|
|
2022
Q4 | $29.2K | Buy |
10,551
+2,292
| +28% | +$5.15K | ﹤0.01% | 5109 |
|
|
2022
Q3 | $19K | Sell |
8,259
-239
| -3% | -$388 | ﹤0.01% | 5429 |
|
|
2022
Q2 | $13K | Sell |
8,498
-3,045
| -26% | -$7.66K | ﹤0.01% | 5648 |
|
|
2022
Q1 | $56K | Sell |
11,543
-10,390
| -47% | -$85K | ﹤0.01% | 5599 |
|
|
2021
Q4 | $324K | Buy |
21,933
+8,278
| +61% | +$165K | ﹤0.01% | 4996 |
|
|
2021
Q3 | $295K | Buy |
13,655
+3,275
| +32% | +$70.5K | ﹤0.01% | 4942 |
|
|
2021
Q2 | $170K | Sell |
10,380
-25,702
| -71% | -$489K | ﹤0.01% | 5092 |
|
|
2021
Q1 | $855K | Buy |
36,082
+11,137
| +45% | +$333K | ﹤0.01% | 4359 |
|
|
2020
Q4 | $595K | Sell |
24,945
-2,191
| -8% | -$34.9K | ﹤0.01% | 4398 |
|
|
2020
Q3 | $320K | Sell |
27,136
-3,799
| -12% | -$40.9K | ﹤0.01% | 4667 |
|
|
2020
Q2 | $324K | Buy |
30,935
+13,136
| +74% | +$118K | ﹤0.01% | 4627 |
|
|
2020
Q1 | $128K | Sell |
17,799
-3,104
| -15% | -$32.2K | ﹤0.01% | 4940 |
|
|
2019
Q4 | $281K | Sell |
20,903
-618
| -3% | -$8.8K | ﹤0.01% | 4764 |
|
|
2019
Q3 | $332K | Buy |
21,521
+4,478
| +26% | +$58.2K | ﹤0.01% | 4654 |
|
|
2019
Q2 | $225K | Sell |
17,043
-592
| -3% | -$8.08K | ﹤0.01% | 4911 |
|
|
2019
Q1 | $310K | Sell |
17,635
-1,315
| -7% | -$20.6K | ﹤0.01% | 4604 |
|
|
2018
Q4 | $217K | Sell |
18,950
-4,754
| -20% | -$57.5K | ﹤0.01% | 4858 |
|
|
2018
Q3 | $337K | Sell |
23,704
-41,064
| -63% | -$583K | ﹤0.01% | 4709 |
|
|
2018
Q2 | $981K | Sell |
64,768
-90
| -0.1% | -$1.52K | ﹤0.01% | 4014 |
|
|
2018
Q1 | $878K | Buy |
64,858
+1,450
| +2% | +$27.5K | ﹤0.01% | 4012 |
|
|
2017
Q4 | $1.5M | Buy |
63,408
+2,010
| +3% | +$47.4K | ﹤0.01% | 3603 |
|
|
2017
Q3 | $1.14M | Buy |
61,398
+7,465
| +14% | +$170K | ﹤0.01% | 3750 |
|
|
2017
Q2 | $1.86M | Buy |
53,933
+53,683
| +21,473% | +$1.48M | ﹤0.01% | 3265 |
|
|
2017
Q1 | $5K | Buy |
+250
| New | +$3.4K | ﹤0.01% | 6030 |
|
Other funds holding PLSE
VCM
PCM
GAM
LP
Wells Fargo's PLSE Position: Q1 2026 in Review
Wells Fargo reduced its Pulse Biosciences (PLSE) stake by 58% in Q1 2026, selling an estimated $239K and leaving 9,195 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #4706.
Wells Fargo first reported a position in PLSE in Q1 2017 and has held it in 37 quarters since. The position peaked at $1.86M in Q2 2017. 96 funds tracked by Wall St. Rank hold PLSE as of Q1 2026.
- Wells Fargo held 9,195 shares of Pulse Biosciences worth $199K as of Q1 2026.
- Wells Fargo sold 12,954 Pulse Biosciences shares in Q1 2026, an estimated $239K.
- Pulse Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4706 holding.
- Wells Fargo first reported a position in Pulse Biosciences in Q1 2017 and has held it in 37 quarters since.
- Wells Fargo's Pulse Biosciences position peaked at $1.86M in Q2 2017.
- 96 funds tracked by Wall St. Rank held Pulse Biosciences as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.